Several studies have proven the favorable efficacy and safety of VEGFR inhibitors and inhibitors of other tumor-associated targets (including EGFR, FGFR, BRAF, c-Met, HDAC, tubulin, ERα and PIM1) combination therapy in patients with tumors. This evidence concerns the gene BRAF and neoplasm.